Clearside Bio loses nearly half its value pre-market as lead eye drug fails pivotal test
Eye drug developer Clearside Biomedical $CSLD said late-stage data showed its experimental treatment, Xipere, did not induce an additional benefit when used in tandem with Regeneron’s $REGN flagship Eylea in patients with retinal vein occlusion (RVO), a common cause of sudden, painless, loss of vision in one eye.
This Phase III failure has prompted the company to abandon the development of a Xipere (formerly suprachoroidal CLS-TA) combination therapy for RVO, and sent its shares plummeting 46% in pre-market trading.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.